Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 2 | Arthritis Research & Therapy

Figure 2

From: NF-κB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor

Figure 2

Effect of dehydroxymethylepoxyquinomicin on differentiation of osteoclasts in ankle joints of mice with collagen-induced arthritis. After taking radiographs (a-c), the ankle joints were histochemically examined for tartrate-resistant acid phosphatase-positive cells (d-i). (a), (d) and (g) Typical joint of an arthritic mouse treated with vehicle alone. (b), (e) and (h) Typical joint of an arthritic mouse treated with dehydroxymethylepoxyquinomicin. (c), (f) and (i) Joint of an age-matched normal mouse. Arrow, multinucleated giant osteoclasts.

Back to article page